北京双鹭药业股份有限公司 北京双鹭药业股份有限公司（以下简称"公司"）第九届董事会独立董事专门会议第四 次会议于 2025 年 4 月 21 日以现场方式在公司总部会议室（北京海淀区碧桐园一号楼四层） 召开，会议通知于 2025 年 4 月 14 日以通讯方式送达给全体独立董事，经独立董事推举， 本次会议由程隆云女士主持，会议应出席独立董事 2 名，现场出席 2 名。本次会议的召集、 召开符合《公司法》和《公司章程》等有关法律、法规，会议合法有效。与会独立董事审 议了如下议案： 二、审议事项 会议以投票表决方式，审议了以下议案： （一）审议通过了《关于 2024 年度利润分配预案的议案》 根据《上市公司独立董事规则》、《深圳证券交易所上市公司自律监管指引第 1 号-主板 上市公司规范运作》和《公司章程》等相关规定，我们作为公司独立董事，在认真审阅相 关资料后，就公司《2024 年度利润分配预案》的议案发表如下意见： 公司《2024 年度利润分配预案》是依据公司实际情况制定的，符合《公司法》、《公司 章程》中关于利润分配的相关规定，符合中国证监会鼓励上市公司现金分红，给予投资者 稳定、合理回报指导意见的要求。我 ...

一、主要会计数据和财务指标 前十大流通股东累计持有： 26633.31万股，累计占流通股比： 31.26%，较上期变化： -681.08万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 新乡白鹭投资集团有限公司 | 15974.00 | 18.76 | 不变 | | 徐明波 | 5810.16 | 6.82 | 不变 | | 香港中央结算有限公司 | 818.87 | 0.96 | -330.26 | | 中国银河（601881）证券股份有限公司约定购回专用账 | | | | | 户 | 800.66 | 0.94 | 23.44 | | 孙伟峰 | 607.99 | 0.71 | 109.19 | | 肖燕丽 | 596.35 | 0.70 | 不变 | | 招商银行股份有限公司-南方中证1000交易型开放式指数 | | | | | 证券投资基金 | 595.57 | 0.70 | 新进 | | 黄壮平 | 497.37 | 0.58 | 不变 | | 大成基金-农业银行-大成中证金融资产 ...

Financial Performance - The company's operating revenue for 2024 was ¥660,419,604.31, a decrease of 35.15% compared to ¥1,018,358,696.85 in 2023[6]. - The net profit attributable to shareholders for 2024 was a loss of ¥74,065,657.76, representing a decline of 117.77% from a profit of ¥416,691,942.89 in 2023[6]. - The net cash flow from operating activities decreased by 51.00% to ¥225,487,183.11 in 2024, down from ¥460,197,296.50 in 2023[6]. - The basic earnings per share for 2024 was -¥0.07, a drop of 117.07% from ¥0.41 in 2023[6]. - Total assets at the end of 2024 were ¥5,979,019,318.74, a decrease of 4.76% from ¥6,277,761,845.44 at the end of 2023[6]. - The company reported a significant decline in the net profit after deducting non-recurring gains and losses, which was ¥82,336,980.01 in 2024, down 64.75% from ¥233,590,683.69 in 2023[6]. - The company achieved a total revenue of ¥660,419,604.31, a year-on-year decrease of 35.15%[58]. - The net profit attributable to shareholders was -¥74,065,657.76, representing a year-on-year decline of 117.77%[58]. - The company invested ¥283,075,167.99 in R&D, down 24.91% compared to the previous year[58]. Dividend Distribution - The company plans to distribute a cash dividend of 0.20 RMB per 10 shares to all shareholders, based on a total of 1,027,350,000 shares[4]. - The company distributed a cash dividend of 1.5 RMB per 10 shares, totaling 154,102,500 RMB based on a total share capital of 1,027,350,000 shares as of December 31, 2023[147]. - The cash dividend policy has been consistent with the company's articles of association and the resolutions of the annual general meeting[148]. - The total distributable profit for the reporting period is 3,734,614,755.77 RMB, with the cash dividend amounting to 20,547,000 RMB, representing 100% of the profit distribution[148]. - The company has maintained a stable cash dividend policy since its listing, adhering to regulatory requirements and ensuring transparency in decision-making[146]. - The company has not made any adjustments to its cash dividend policy during the reporting period, maintaining its commitment to shareholder returns[148]. Research and Development - The company invested ¥283,075,167.99 in R&D, down 24.91% compared to the previous year[58]. - The company plans to launch two second-generation gene engineering blockbuster products in the next two years, significantly enhancing its competitiveness in biopharmaceuticals[55]. - The company has a rich pipeline of potential products, including long-acting protein drugs and specialty patented drugs, across various therapeutic areas such as oncology and cardiovascular diseases[56]. - The company is actively adjusting its marketing strategies to adapt to changes in the pharmaceutical market and is focusing on the development of innovative products[59]. - The company has made significant progress in the development of key R&D projects and new technology platforms, enhancing its engineering capabilities in eukaryotic expression systems[60]. - The company is committed to advancing its research and development efforts, with a strong pipeline of innovative therapies aimed at addressing unmet medical needs[63]. Market Challenges - The company faced challenges in the pharmaceutical industry due to intensified competition and price reductions from centralized procurement policies, impacting profit margins and R&D investments[29]. - The average price reduction from centralized procurement has exceeded 50%, with some products seeing price drops of over 80%[31]. - The average price reduction of selected drugs in the national procurement process exceeds 50%, forcing companies to innovate[32]. - The ongoing national centralized drug procurement will continue to expand, with 435 drugs successfully procured since the pilot began in November 2018, impacting profit margins for many products[106]. - The company faces risks from price reductions due to intensified competition in the centralized procurement process, potentially leading to a micro-profit era for some products[108]. Corporate Governance - The company operates independently from its controlling shareholders, with a complete and autonomous business and operational capability[115]. - The company has established a comprehensive independent asset procurement and supply system, ensuring no asset encroachment by major shareholders[116]. - The company has a fully independent financial department with its own accounting personnel and bank accounts, ensuring no interference from controlling shareholders in fund usage[118]. - The company has a clear ownership structure, with no major shareholder infringing on its assets[116]. - The company has established comprehensive governance documents to ensure compliance with laws and regulations[153]. - The internal control system has been continuously improved, ensuring risk controllability through a structured governance mechanism[152]. Environmental Responsibility - The company has invested approximately 7 million RMB in environmental protection facilities, and the local government has not yet started collecting environmental protection taxes[166]. - The company has established a charity foundation with an initial capital of 8 million RMB to support patients facing economic difficulties due to major illnesses, providing a total of 950,000 RMB in donations in 2024[169][170]. - The company has implemented a comprehensive environmental monitoring plan in accordance with its pollution discharge permit requirements[164]. - The company has received no administrative penalties related to environmental issues during the reporting period[167]. - The company has developed a robust wastewater treatment and air pollution control system, ensuring stable operation of its facilities[163]. Legal Matters - The company is involved in ongoing arbitration cases with a total claim amount of RMB 24,008,450.30 related to contract disputes[180]. - The company has executed all arbitration rulings and is currently in the process of appealing certain decisions[180]. - The company filed a lawsuit against Nanjing Cavendish for a breach of contract regarding the Apixaban technology transfer, seeking the return of CNY 4.8 million and a penalty of CNY 6 million[181]. - The company is currently involved in multiple legal disputes with Nanjing Cavendish, including a claim for CNY 9.315 million related to the Dasatinib technology transfer contract[182]. - The company has been awarded a judgment of CNY 6 million in compensation from Nanjing Cavendish in a previous case, which is currently under appeal[183]. Employee Management - The total number of employees at the end of the reporting period is 889, with 424 in the parent company and 465 in major subsidiaries[142]. - The professional composition includes 343 production personnel, 415 technical personnel, 50 sales personnel, 14 financial personnel, and 67 administrative personnel[143]. - The training plan for employees includes comprehensive arrangements for training schedules, content, and evaluation methods, ensuring effective skill development[145]. - The company has a performance evaluation system linking employee performance to compensation, with senior management evaluated by the board's committees[144]. - The company is enhancing its talent acquisition by recruiting high-end technical and versatile talents, while also focusing on internal talent development and retention mechanisms[104].

Financial Performance - The company's revenue for Q1 2025 was ¥168,896,131.59, a decrease of 31.10% compared to ¥245,116,238.48 in the same period last year[5] - Net profit attributable to shareholders was ¥45,968,405.62, down 34.46% from ¥70,134,618.06 year-on-year[5] - The basic earnings per share decreased by 42.86% to ¥0.04 from ¥0.07 in the same period last year[5] - The company reported a significant decline in net profit excluding non-recurring gains and losses, which was ¥21,141,816.50, down 79.19% from ¥101,583,927.04 in the previous year[5] - The company's net profit for the current period is CNY 45,617,183.33, a decrease of 34.5% compared to CNY 69,675,806.49 in the previous period[20] - Operating profit for the current period is CNY 48,346,156.71, down 32.0% from CNY 71,156,814.33 in the previous period[20] - The company reported a net profit margin decline due to increased operating costs, impacting overall profitability[18] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥55,992,394.20, a decline of 152.45% compared to ¥106,747,075.24 in the previous year[5] - The company reported a net cash outflow from operating activities of CNY -55,992,394.20, compared to a net inflow of CNY 106,747,075.24 in the previous period[23] - Investment activities resulted in a net cash outflow of CNY -131,848,452.89, compared to CNY -24,793,699.08 in the previous period[23] - The company's cash and cash equivalents at the end of the period decreased to CNY 212,037,406.38 from CNY 621,996,815.09 at the end of the previous period[23] - Cash and cash equivalents decreased to ¥328,747,917.07 from ¥411,958,243.66, representing a decline of 20.1%[14] Operating Costs and Expenses - Total operating costs increased to ¥155,955,363.45, up 14.2% from ¥136,620,657.72 in the previous period[18] - The company incurred total sales expenses of CNY 19,904,477.41, an increase of 16.9% from CNY 17,035,038.54 in the previous period[20] - Research and development expenses increased slightly to CNY 28,942,931.49 from CNY 28,053,862.46 in the previous period[20] Assets and Liabilities - Total assets at the end of the reporting period were ¥6,064,702,839.06, reflecting a 1.43% increase from ¥5,979,019,318.74 at the end of the previous year[5] - Total assets increased to ¥6,064,702,839.06 from ¥5,979,019,318.74, reflecting a growth of 1.4%[16] - Total liabilities rose to ¥438,437,416.35, an increase of 10.1% from ¥398,371,079.36[16] - The equity attributable to shareholders increased by 0.82% to ¥5,618,416,348.02 from ¥5,572,447,942.40 at the end of the previous year[5] - Shareholders' equity increased to ¥5,626,265,422.71 from ¥5,580,648,239.38, a growth of 0.8%[16] Fair Value and Financial Changes - The company's financial expenses increased by 44.14% year-on-year, primarily due to reduced interest income from lower interest rates[9] - The fair value changes in financial assets increased by 157.94%, attributed to the market value fluctuations of holdings in Shouyao Holdings and Xinghao Pharmaceutical[9] - The company reported a significant fair value change gain of CNY 25,524,228.94, compared to a loss of CNY -44,049,648.74 in the previous period[20] Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[18]

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的硝酸甘油喷雾剂（商品名：立生乐?）《药品注册证书》，现将药品相关情况介绍如 下： 一、药品基本信息 登录新浪财经APP 搜索【信披】查看更多考评等级 公司于2023年7月20日向国家药品审评中心递交国内首家上市申请并获得受理。 硝酸甘油喷雾剂为溶液型喷雾剂，通过口腔黏膜直接吸收，无需溶解步骤，通常30秒至1分钟即可起 效，适合紧急情况（如心绞痛急性发作）使用。临床研究显示，患者用药后立即起效者为23.5%，1分 钟之内起效者为62%，2分钟内起效者可高达85.75%。本品与气雾剂相比，其不含抛射剂，通过手动泵 的压力将药液转化为雾状形态；同时药物不气化，系雾滴给药，因而其没有致冷效应，不会使皮肤引起 不适和刺激感，安全性更高，起效更快。临床上主要用于快速缓解或紧急预防冠心病引起的心绞痛发 作。 硝酸甘油喷雾剂在国外上市多年，其安全性和有效性均得到了充分证明。硝酸甘油喷雾剂由德国保时佳 大药厂G.Pohl- ...

证券代码：002038 证券简称：双鹭药业 公告编号：2025-005 北京双鹭药业股份有限公司 关于获得硝酸甘油喷雾剂药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的硝酸甘油喷雾剂（商品名：立生乐®）《药品注册 证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：硝酸甘油喷雾剂 剂 型：喷雾剂 规 格：每瓶 200 喷，每喷重量 48mg 含硝酸甘油 0.4mg 注册分类：化学药品 4 类 生产企业：北京双鹭药业股份有限公司 药品批准文号：国药准字 H20253802 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 7 月 20 日向国家药品审评中心递交国内首家上市申请并获得受理。 硝酸甘油喷雾剂为溶液型喷雾剂，通过口腔黏膜直接吸收，无需溶解步骤，通常 30 秒 至 1 分钟即可起效，适合紧急情况（如心 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 规 格：40mg 注册分类：化学药品4类 生产企业：北京双鹭药业股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的瑞戈非尼片（商品名：欣立尔?）《药品注册证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：瑞戈非尼片 剂 型：片剂 瑞戈非尼（Regorafenib）是一种多靶点酪氨酸激酶抑制剂，广泛应用于多种晚期癌症的治疗。主要适用 于治疗既往接受过以氟尿嘧啶、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗 VEGF治疗、抗EGFR治疗（RAS野生型）的转移性结直肠癌（mCRC）患者；既往接受过甲磺酸伊马替 尼及苹果酸舒尼替尼治疗的局部晚期的、无法手术切除的或转移性的胃肠道间质瘤（GIST）患者；既 往接受过索拉非尼治疗的肝细胞癌（HCC）患者。 原研瑞戈非尼片由拜耳和Onyx联合开发，于2012年9月27日获美国FDA批准上市，2017年3月24日在国 内获批上市 ...

证券代码：002038 证券简称：双鹭药业 公告编号：2025-004 规 格：40mg 注册分类：化学药品 4 类 生产企业：北京双鹭药业股份有限公司 药品批准文号：国药准字 H20253676 北京双鹭药业股份有限公司 关于获得瑞戈非尼片药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的瑞戈非尼片（商品名：欣立尔®）《药品注册证 书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：瑞戈非尼片 剂 型：片剂 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 5 月 22 日向国家药品审评中心递交上市申请并获得受理。 瑞戈非尼（Regorafenib）是一种多靶点酪氨酸激酶抑制剂，广泛应用于多种晚期癌症 的治疗。主要适用于治疗既往接受过以氟尿嘧啶、奥沙利铂和伊立替康为基础的化疗，以 及既往接受过或不适合接受抗 ...

北京双鹭药业股份有限公司 关于获得替米沙坦氨氯地平片（Ⅱ）药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 北京双鹭药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的替米沙坦氨氯地平片（Ⅱ）（商品名：立生源®） 《药品注册证书》，现将药品相关情况介绍如下： 一、药品基本信息 药品名称：替米沙坦氨氯地平片（Ⅱ） 剂 型：片剂 规 格：每片含替米沙坦 40mg 与苯磺酸氨氯地平 5mg（按氨氯地平计） 注册分类：化学药品 4 类 证券代码：002038 证券简称：双鹭药业 公告编号：2025-002 药品批准文号：国药准字 H20253588 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品 注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 公司于 2023 年 6 月 25 日向国家药品审评中心递交上市申请并获得受理。 替米沙坦氨氯地平片（Ⅱ）为替米沙坦和氨氯地平组成的复方制剂。替米沙坦属于血 管紧张素 II 受体拮抗剂，通过阻断血管紧张素 II 的 ...

Financial Performance Expectations - The company expects a net profit loss of 32 million yuan for 2024, a decrease of 107.68% compared to the previous year's profit of 52 million yuan[3]. - Total profit is projected to be a loss of 62 million yuan, down 113.34% from a profit of 82 million yuan in the same period last year[3]. - The net profit after deducting non-recurring gains and losses is expected to be 120 million yuan, a decrease of 48.63% from 100 million yuan in the previous year[3]. - The basic earnings per share is projected to be a loss of 0.03 yuan per share, compared to a profit of 0.05 yuan per share last year[3]. Reasons for Profit Decline - The significant decline in net profit is primarily due to a decrease in product prices leading to reduced operating income[5]. - Fluctuations in the stock prices of held trading financial assets resulted in a net profit decrease of 178 million yuan, contrasting with a profit increase of 197 million yuan from stock price fluctuations in 2023[5]. Communication and Reporting - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant discrepancies[4]. - The financial data provided is preliminary and will be detailed in the 2024 annual report, urging investors to exercise caution[6].